Peptide to Assist Botulinum Toxin Type A

Jun 3, 2014 | Contact Author | By: Rachel Grabenhofer
Your message has been sent.
(click to close)
Contact the Author
Save
This item has been saved to your library.
View My Library
(click to close)
Save to My Library
Title: Peptide to Assist Botulinum Toxin Type A
Botulinum Toxin Type Ax peptidex anti-agingx anti-wrinklex
  • Article
  • Keywords/Abstract
  • Related Material

Lipotec has launched a peptide positioned to topically assist Botulinum Toxin Type A while "waiting for the next injection." Argirelox (INCI: Water (Aqua) (and) Glycerin (and) Acetyl Hexapetide-8 (and) Pentapeptide-18 (and) Citric Acid (and) Caprylyl Glycol) was shown in vivo to enhance the anti-aging effects of  Botulinum Toxin Type A in a panel of 22 women, of an average age of 51, who received 50 UI of the toxin in the crow's feet and frontal region. After the session, they applied either a cream containing 10% peptide solution or a placebo, twice daily for 6 months. Reductions of glabellar lines and crow’s feet wrinkles were more noticeable, almost three times greater, when the injection was complemented with the topical treatment containing the peptide, compared to that achieved with the placebo. This benefit was also noticeable after 6 months.

The Argirelox peptide targets two factors for muscle contraction to fight expression wrinkles: it reduces acetylcholine release by competing for a position in the SNARE complex, and it blocks the entrance from calcium ions, which are necessary for vesicle fusion with the membrane. As a result, muscles are relaxed and wrinkles are attenuated.